CNO Financial Group, Inc.
In the published model solve dated 2026-Q2, anchored at $56.75, CNO Financial Group, Inc. (CNO) is priced for 16.4% return on equity. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• CNO sells supplemental health, life and annuity products to middle-income and retirement-age households in amounts too small to interest a national carrier's sales force, reaching them through a channel mix its annual report describes as ⟦"exclusive agents, independent producers (some of whom sell one or more of our product lines exclusively) and direct marketing"⟧. • The stock changes hands at roughly twice book value, a price that assumes the company sustains a return on equity near 16.6% wh
Is CNO overvalued? See what's priced in →
347 institutional managers reported holding CNO in 13F filings for the quarter ended 2026-03-31. Together they hold about 78% of the company; the top 10 hold 43%. 37 opened new positions that quarter. Held by BlackRock, State Street, Franklin Resources, among others. On the short side, 1.9M shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (2.3 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
CNO has cut its share count 28.2% over the past five years, spending $1.28B on repurchases. It pays a dividend, and has for 14 years running, raised 13 years straight; the current rate is $0.67 a share annually. Cash returned over the past three years: $184.60M in dividends and $815.40M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at CNO over the trailing three years. Absence is a fact about the company, not a signal. 21 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
CNO's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-10 | -4.6% | -2.3% |
| 2023-11-09 | +0.4% | +11.4% |
| 2024-02-24 | -2.9% | -2.3% |
| 2024-05-07 | -0.3% | +1.2% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
CNO's latest 8-K filings: 2026-09-01 (items 7.01, 9.01); 2026-07-30 (items 2.02, 9.01); 2026-05-13 (items 5.07); 2026-04-30 (items 2.02, 9.01); 2026-02-11 (items 5.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.